新機能のお知らせ
各銘柄ページに新設された「適時開示」タブより、最新の適時開示情報を簡単にご覧いただけるようになりました。
ぜひご利用ください。
【新機能】適時開示情報が閲覧可能に!
ここから本文です
投稿一覧に戻る

めでぃしのば応援の掲示板

esults: EC-DB-43/51 completed-0-6mon; 8/51-stops
(0-deaths on study drug; 4-study drug intolerance (intol);4-unable to travel (utt)); EC-OLE-35/43 completed-6-12mon; 8/43-stops (1-death off study drug; 4-intol 4-utt)
EC-WO:32/35 completed per protocol-12mon +2weeks;
3/35-stops (0-deaths off study drug; 3-utt); EC-PWO-29/
51 subjects alive at OLE completion by last subject
entered-15-37mon; (22/51-deaths off study drug post
DB-OLE). Per-protocol (PP) completers (PPwoNIV {14}
mean ¼ 34.8 mon (95% CI ¼ 32.7 to 36.9); PPwNIV {18}
mean ¼ 9.4 mon (95% CI ¼ 26.4 to 32.3)) had better
survival (p ¼ 0.0004, Kaplan-Meier) than non-per-proto-
col (nPP) completers (nPPwoNIV {6} mean ¼ 24.0 mon
(95% CI ¼ 16.0 to 32.0); PPwNIV {13} mean ¼ 20.5 mon
(95% CI ¼ 16.6 to 24.3)].